MakeO's latest fundraise underscores a broader shift in India's consumer health and medtech landscape: investors are still backing category leaders, but with a sharper focus on disciplined expansion and cross-border potential. The company, best known for Toothsi, has secured ₹90 crore in a round led by existing and new backers, according to people familiar with the transaction. The capital is expected to support geographic expansion, brand building, and operational scale-up as the company pushes deeper into India while preparing for a larger footprint in Southeast Asia.
The deal arrives at a time when the clear aligner segment is moving from early-adopter enthusiasm toward a more competitive, execution-heavy phase. Toothsi has built its business around at-home dental assessments and invisible aligner treatments, targeting urban consumers who want a more convenient and discreet alternative to traditional braces. That proposition has helped the brand establish visibility in a market where dental care has historically been fragmented, under-penetrated, and often driven by offline clinics.
Expansion Playbook
For MakeO, the new capital is likely to be deployed in a measured way. India remains the core market, and the company is expected to deepen its presence in metros and tier-1 cities while broadening access in select tier-2 markets where affordability and awareness are improving. The Southeast Asia push is strategically significant because the region offers a similar mix of rising disposable incomes, growing cosmetic dentistry demand, and digitally engaged consumers who are increasingly open to telehealth-style care journeys.
Cross-border expansion, however, is not simply a matter of transplanting an Indian consumer brand into a new geography. Dental care is regulated differently across markets, clinical workflows vary, and consumer acquisition costs can rise quickly if a company lacks local trust and practitioner networks. That means MakeO will likely need to invest not only in marketing, but also in clinical infrastructure, partnerships, and country-specific compliance.
The funding also signals that investors continue to see value in brands that sit at the intersection of healthcare and consumer technology. Unlike many pure-play consumer startups, dental aligner businesses can build recurring revenue streams, high-ticket treatment plans, and stronger patient retention if execution is sound. But they also face scrutiny around treatment outcomes, customer experience, and the ability to convert online interest into clinically appropriate cases.
Market Pressure Builds
The raise comes against a backdrop of heightened caution in startup funding. Venture investors in India have become more selective, rewarding companies that can demonstrate a credible path to profitability or at least efficient growth. In that environment, a company like MakeO must show that it can scale without overextending on customer acquisition or compromising service quality.
That challenge is especially relevant in the direct-to-consumer healthcare segment, where growth can be fast but operational complexity is high. Clear aligner treatment requires diagnostic accuracy, patient adherence, and ongoing monitoring. Any mismatch between promise and delivery can quickly affect brand reputation, particularly in a category where consumers are making a meaningful financial and health-related commitment.
Still, the company's ability to raise fresh capital suggests that backers believe the category has room to expand. India's dental care market remains relatively under-served compared with developed economies, and cosmetic dentistry is gradually moving into the mainstream among younger consumers. If MakeO can convert that demand into a repeatable, clinically credible model, it could emerge as one of the more durable names in the segment.
The Southeast Asia opportunity may also help diversify revenue beyond India, where competition is intensifying and consumer acquisition is becoming more expensive. Markets such as Singapore, Malaysia, Thailand, and Indonesia offer different entry points, but they also require localized pricing, regulatory adaptation, and market education. For MakeO, the next phase will be less about proving the concept and more about proving that the model travels.
The ₹90 crore infusion is therefore more than a routine growth round. It is a signal that investors still see white-space in digital-first dental care, but only for operators that can combine clinical credibility, operational discipline, and regional ambition. In a startup market that increasingly rewards restraint over exuberance, MakeO's challenge will be to expand without losing the trust that made Toothsi a recognizable brand in the first place.